Organisation paid for research Program year 2024 Source: CMS Open Payments

Pharmaceutical Research Organization

Neither a doctor nor a teaching hospital

Research payments

$4,042,551

788 payments

Through program year 2024, Pharmaceutical Research Organization is reported as receiving $4,042,551 in research payments, across 788 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$13,539	7
2023	Research	$359,114	95
2022	Research	$339,078	118
2021	Research	$1,885,644	280
2020	Research	$827,465	171
2019	Research	$617,710	117

Breakdown

Who paid Research payments · program years 2019–2024

Pfizer Inc. $2,943,503 554 payments
GlaxoSmithKline, LLC. $565,447 160 payments
Merck Sharp & Dohme Corporation $254,022 8 payments
Novavax Inc $240,065 53 payments
AstraZeneca Pharmaceuticals LP $21,008 6 payments
Sekisui Diagnostics LLC $13,845 2 payments
Bayer HealthCare Pharmaceuticals Inc. $4,661 5 payments

Studies the money was for Research payments · program years 2019–2024

A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Infants $1,700,929 159 payments
A Phase 2B Randomized Observerblinded Trial to Describe the Safety Tolerability and Immunogenicity of Menabcwy Administered on 2 Different Dosing Schedules in Healthy Participants 11 to 15 Years of Age $531,434 200 payments
A Phase 3 Singlearm Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through 17 Years of Age $401,406 82 payments
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 $234,485 51 payments
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED $187,363 5 payments
A Phase 2 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Conjugate Vaccines in Healthy Infants $183,756 74 payments
Rota-096 $155,234 33 payments
Menb Rec 2Nd Gen-023 (V72_57) $115,107 76 payments
A Phase III, Randomized, Controlled, Observer-Blind Study to Demonstra $99,112 5 payments
Menb Rec 2Nd Gen-038 (V72_72) $87,236 30 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.